efa blu (paziņots 2015.) kapsula
es pēc new syform s.r.l. pasūtījuma - kapsula
citrofos (paziņots 2013.) pulveris
es pēc new syform s.r.l. pasūtījuma - pulveris
essenziale 8+® (paziņots 2013.) pulveris
es pēc new syform s.r.l. pasūtījuma - pulveris
ontozry
angelini pharma s.p.a - cenobamate - epilepsija - antiepileptics, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.
maalox 460 mg/400 mg/4,3 ml suspensija iekšķīgai lietošanai
opella healthcare france s.a.s., france - aluminii hydroxidum, magnija hydroxidum - suspensija iekšķīgai lietošanai - 460 mg/400 mg/4,3 ml
daxocox
ecuphar nv - enflicoxib - pretiekaisuma un pretreimatisma līdzekļi - suņi - for the treatment of pain and inflammation associated with osteoarthritis (or degenerative joint disease) in dogs.
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - cukura diabēts, 2. tips - cukura diabēts - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
trittico ac 150 mg ilgstošās darbības tabletes
aziende chimiche riunite angelini francesco - a.c.r.a.f. s.p.a., italy - trazodona hidrohlorīds - ilgstošās darbības tablete - 150 mg
microven fee (2022.) šķidrums
šķidrums
vischio fee (2022.) šķidrums
šķidrums